Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 20/20 | 0.77 |
| ▸ | ESRRB | O95718 | 10/20 | 0.66 |
| ▸ | ESR1 | P03372 | 7/20 | 0.66 |
| ▸ | ESRRA | P11474 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20842014 | 0.88 | ESRRG (0.98) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL24354483 | 0.84 | ESRRG (0.91) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL20842168 | 0.82 | ESRRG (0.98) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL21026578 | 0.81 | ESRRG (0.85) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL20842053 | 0.80 | ESRRG (1.00) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL20978480 | 0.78 | ESRRG (0.84) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL20842127 | 0.77 | ESRRG (0.98) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL30065746 | 0.77 | ESRRG (0.78) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL20842100 | 0.76 | ESRRG (0.98) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL20842117 | 0.75 | ESRRG (0.98) | ESRRGESRRBESR1ESRRAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393583-A1 | METHOD FOR THE TREATMENT OF PANCREATITIS | NOVMETAHEALTH CO., LTD. (KR) | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393583-A1 | METHOD FOR THE TREATMENT OF PANCREATITIS | PNLIP, AMY2A, CEL | ESRRG 2148/4885ESRRB 1890/4885ESR1 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.